In mice with induced colitis, a compound called EEPZ, derived from wheat bran, changes the composition of gut bacteria by increasing Lactobacillus vaginalis and decreasing Desulfovibrio.

We analyzed the available evidence and found that in mice with induced colitis, a compound called EEPZ — made from enzymatically hydrolyzed wheat bran-derived zinc phytate — is associated with changes in gut bacteria. Specifically, the evidence we’ve reviewed shows an increase in Lactobacillus vaginalis and a decrease in Desulfovibrio [1]. These shifts in bacterial populations are noted in the context of colitis, a condition involving gut inflammation. So far, eight studies or assertions support this observation, and none contradict it. However, we only have one specific assertion to work from, and all of the supporting data come from the same source. This means we cannot yet say whether these changes are consistent across different mouse models, dosages, or time frames. We also don’t have data on whether these bacterial shifts lead to measurable improvements in inflammation or symptoms. The gut microbiome is complex, and changes in one or two bacterial types don’t automatically mean the overall ecosystem becomes healthier or more balanced. We don’t know if Lactobacillus vaginalis is beneficial in this context, or if reducing Desulfovibrio has any real impact on colitis progression. The evidence we’ve reviewed so far is limited in scope and doesn’t include human data or long-term outcomes. What we’ve found so far suggests that EEPZ may influence gut bacteria in mice with colitis, but we can’t say how meaningful or reliable that effect is. More studies with different designs, larger sample sizes, and clearer health outcomes are needed to understand what this means beyond the lab. For now, if you’re considering this compound for gut health, the evidence is too early and too narrow to draw practical conclusions.